Related Experiment Videos
Calcium antagonists and the diabetic hypertensive patient
1Steno Diabetes Center, Copenhagen, Denmark.
Insights
Diabetic nephropathy, a common complication, causes kidney damage and high blood pressure. Lowering blood pressure effectively slows disease progression and reduces kidney damage in diabetic patients.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Diabetic nephropathy affects 40% of diabetic patients, leading to kidney disease and hypertension.
- It is a leading cause of end-stage renal disease (ESRD) in the Western world.
- Diabetic nephropathy significantly increases morbidity and mortality in diabetic populations.
Purpose of the Study:
- To investigate the complex relationship between arterial blood pressure and diabetic nephropathy.
- To highlight the impact of blood pressure management on diabetic kidney disease progression.
- To review the effects of antihypertensive medications on renal function in diabetics.
Main Methods:
- Observational analysis of diabetic patients with and without nephropathy.
- Review of studies on blood pressure, fluid/sodium balance, and hormonal profiles in diabetic renal disease.
- Examination of the impact of blood pressure reduction on albuminuria and renal function.
Main Results:
- Elevated blood pressure is an early and common feature of diabetic nephropathy.
- Fluid and sodium retention occur in diabetic renal disease.
- Reduced nocturnal blood pressure decline is linked to increased cardiovascular risk in these patients.
- Raised blood pressure accelerates diabetic nephropathy development and progression.
Conclusions:
- Effective blood pressure reduction is crucial for managing diabetic nephropathy.
- Lowering blood pressure reduces albuminuria, slows nephropathy progression, and delays renal insufficiency.
- Certain antihypertensive drugs (calcium antagonists, ACE inhibitors) improve renal hemodynamics.
Abstract:
Roughly 40% of all diabetic patients, whether insulin dependent or not, develop persistent albuminuria (over 300 mg/24 hr), a decrease in the glomerular filtration rate, and elevated blood pressure, ie, diabetic nephropathy. Diabetic nephropathy is the single most important cause of end stage renal disease in the Western world, and accounts for over a quarter of all end stage renal disease. It also is a major cause of the increased morbidity and mortality seen in diabetic patients; for example, the cost of end stage renal care in the United States currently exceeds +1.8 billion per year for diabetic nephropathy alone and is rapidly rising. Increased arterial blood pressure is an early and common finding in incipient and overt diabetic nephropathy. Fluid and sodium retention with normal concentrations of active renin, angiotensin I and II, and aldosterone has been demonstrated in diabetic renal disease. An impaired nocturnal decline in blood pressure is more prevalent in patients with diabetic nephropathy and autonomic neuropathy, and may contribute to the enhanced cardiovascular morbidity found in such patients. Moreover, raised blood pressure accelerates both the development and progression of diabetic nephropathy in insulin-dependent and non-insulin-dependent diabetes. The relationship between arterial blood pressure and diabetic nephropathy thus seems to be a complex one: nephropathy increasing blood pressure and blood pressure accelerating the course of nephropathy. Effective blood pressure reduction reduces albuminuria, delays the progression of nephropathy, and postpones renal insufficiency in diabetic nephropathy. Calcium antagonists and angiotensin converting enzyme inhibitors induce an acute increase in the glomerular filtration rate, renal plasma flow, and renal sodium excretion.(ABSTRACT TRUNCATED AT 250 WORDS)